IL-32 might be a potential new therapeutic avenue for MS
Nov 18, 2015
November 18, 2015
In a recent study entitled “” a team of researchers investigated whether interleukin (IL)-32, a cytokine with an established role in rheumatoid arthritis, has a protective function in a mouse model of human multiple sclerosis (MS). The study was published in the journal Oncotarget.